Binimetinib for the treatment of NRAS-mutant melanoma

Paola Queirolo, Francesco Spagnolo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Activating NRAS mutations occur in approximately 15–20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in this group of patients. Areas covered: The purpose of this paper was to review the safety, activity and efficacy of the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma, as well as to discuss future therapeutic perspectives such as multiple pathways, targeted therapy, and combinations with immunotherapy. Expert commentary: Only a modest progression-free survival (PFS) benefit was observed in NRAS-mutated patients who received binimetinib compared with dacarbazine in a randomized phase 3 clinical trial, with no improvement in overall survival. Nevertheless, binimetinib represents another promising treatment option for advanced melanoma and the first molecularly targeted therapy for the NRAS-mutant population. Binimetinib may also have a role in treating NRAS-mutated melanoma patients after failure of immunotherapy.

Original languageEnglish
Pages (from-to)985-990
Number of pages6
JournalExpert Review of Anticancer Therapy
Volume17
Issue number11
DOIs
Publication statusPublished - Nov 2 2017

Fingerprint

Melanoma
Mitogen-Activated Protein Kinase Kinases
Mutation
Immunotherapy
Therapeutics
Dacarbazine
Phase III Clinical Trials
Disease-Free Survival
MEK162
Randomized Controlled Trials
Safety
Survival
Population
Neoplasms

Keywords

  • binimetinib
  • MEK
  • MEK162
  • Melanoma
  • NRAS
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Binimetinib for the treatment of NRAS-mutant melanoma. / Queirolo, Paola; Spagnolo, Francesco.

In: Expert Review of Anticancer Therapy, Vol. 17, No. 11, 02.11.2017, p. 985-990.

Research output: Contribution to journalArticle

Queirolo, Paola ; Spagnolo, Francesco. / Binimetinib for the treatment of NRAS-mutant melanoma. In: Expert Review of Anticancer Therapy. 2017 ; Vol. 17, No. 11. pp. 985-990.
@article{8a3c0a92a24f4dc395c305b768062247,
title = "Binimetinib for the treatment of NRAS-mutant melanoma",
abstract = "Introduction: Activating NRAS mutations occur in approximately 15–20{\%} of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in this group of patients. Areas covered: The purpose of this paper was to review the safety, activity and efficacy of the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma, as well as to discuss future therapeutic perspectives such as multiple pathways, targeted therapy, and combinations with immunotherapy. Expert commentary: Only a modest progression-free survival (PFS) benefit was observed in NRAS-mutated patients who received binimetinib compared with dacarbazine in a randomized phase 3 clinical trial, with no improvement in overall survival. Nevertheless, binimetinib represents another promising treatment option for advanced melanoma and the first molecularly targeted therapy for the NRAS-mutant population. Binimetinib may also have a role in treating NRAS-mutated melanoma patients after failure of immunotherapy.",
keywords = "binimetinib, MEK, MEK162, Melanoma, NRAS, targeted therapy",
author = "Paola Queirolo and Francesco Spagnolo",
year = "2017",
month = "11",
day = "2",
doi = "10.1080/14737140.2017.1374177",
language = "English",
volume = "17",
pages = "985--990",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Binimetinib for the treatment of NRAS-mutant melanoma

AU - Queirolo, Paola

AU - Spagnolo, Francesco

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Introduction: Activating NRAS mutations occur in approximately 15–20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in this group of patients. Areas covered: The purpose of this paper was to review the safety, activity and efficacy of the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma, as well as to discuss future therapeutic perspectives such as multiple pathways, targeted therapy, and combinations with immunotherapy. Expert commentary: Only a modest progression-free survival (PFS) benefit was observed in NRAS-mutated patients who received binimetinib compared with dacarbazine in a randomized phase 3 clinical trial, with no improvement in overall survival. Nevertheless, binimetinib represents another promising treatment option for advanced melanoma and the first molecularly targeted therapy for the NRAS-mutant population. Binimetinib may also have a role in treating NRAS-mutated melanoma patients after failure of immunotherapy.

AB - Introduction: Activating NRAS mutations occur in approximately 15–20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in this group of patients. Areas covered: The purpose of this paper was to review the safety, activity and efficacy of the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma, as well as to discuss future therapeutic perspectives such as multiple pathways, targeted therapy, and combinations with immunotherapy. Expert commentary: Only a modest progression-free survival (PFS) benefit was observed in NRAS-mutated patients who received binimetinib compared with dacarbazine in a randomized phase 3 clinical trial, with no improvement in overall survival. Nevertheless, binimetinib represents another promising treatment option for advanced melanoma and the first molecularly targeted therapy for the NRAS-mutant population. Binimetinib may also have a role in treating NRAS-mutated melanoma patients after failure of immunotherapy.

KW - binimetinib

KW - MEK

KW - MEK162

KW - Melanoma

KW - NRAS

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85029440722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029440722&partnerID=8YFLogxK

U2 - 10.1080/14737140.2017.1374177

DO - 10.1080/14737140.2017.1374177

M3 - Article

VL - 17

SP - 985

EP - 990

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -